176P Prognostic factors in patients with ovarian cancer enrolled in phase I clinical trials
Ovarian cancer remains a lethal disease, often marked by platinum resistance, highlighting the need for innovative therapies and efficient selection of candidates for early-phase trials. Few studies have characterized outcomes or risks among ovarian cancer patients enrolled in phase I trials to better identify those most likely to benefit.
Authors
- S. Postel-Vinay
- F. Blanc-Durand
- Madona Sakkal (ORCID: https://orcid.org/0000-0002-9015-8359)
- Anna Patrikidou (ORCID: https://orcid.org/0000-0001-5066-601X)
- C. Massard
- Y. Loriot
- C. Baldini
- K. Ouali
- A. Hollebecque
- M-A.L. Audisio
- J. Michels
- A. Leary
- V. Ribrag
- P. Pautier
- A. Marabelle
- A. Gazzah
- R. Bahleda
Institutions
- Institut Gustave Roussy (FR)
Publication Details
- Journal
- ESMO Open
- Published
- 2026-04-01
- DOI
- https://doi.org/10.1016/j.esmoop.2026.106183
- Primary Topic
- Ovarian cancer diagnosis and treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00